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Abstract
Background: Amyotrophic Lateral Sclerosis (ALS) treatment is complicated by the various mechanisms underlying motor
neuron degeneration. Recent studies showed that the blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB) are
compromised in an animal model of ALS due to endothelial cell degeneration. A later study demonstrated a loss of
endothelium integrity in the spinal cords of ALS patients. Since circulating endothelial cells (CECs) in the peripheral blood
are associated with endothelium damage, being detached dysfunctional endothelial cells, we hypothesized that CEC levels
may reflect endothelium condition in ALS patients.
Methodology/Principal Findings: CEC levels were estimated in whole blood smears from ALS patients with moderate stage
(MALS), severe stage (SALS), and healthy controls by CD146 expression using immunocytochemistry. A significant reduction
of CECs was detected in MALS and SALS patients.
Conclusions/Significance: CECs did not predict endothelium state in ALS patients; however, endothelial damage and/or
impaired endothelium repair may occur in ALS leading to BBB/BSCB dysfunction. Reduced CECs in peripheral blood of ALS
patients may indicate different mechanisms of endothelial damage and repair, rather than only detachment of
dysfunctional endothelial cells. Although a potential mechanism of CEC reduction is discussed, establishing a reliable
indicator of endothelial dysfunction/damage is important for evaluation of BBB/BSCB status in ALS patients during disease
progression.
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Introduction
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenera-
tive disorder characterized by motor neuron degeneration in the
brain and spinal cord clinically manifesting as progressive
muscular weakness leading to paralysis and death. Most ALS
cases are sporadic (SALS) with only 5–10% of cases genetically
linked (FALS). Of familial cases, 20% show missense mutations in
the Cu/Zn superoxide dismutase (SOD1) gene [1]. Numerous
hypotheses have been proposed concerning ALS pathogenesis
[2–7], yet limited therapeutic options exist.
Development of an effective treatment for ALS is complicated by
the various underlying disease mechanisms and by the diffuse nature
of motor neuron death. One possible mechanism involved in ALS
pathogenesis is impairment of the blood-brain barrier (BBB) and
blood-spinal cord barrier (BSCB), aggravating motor neuron
damage. Recent findings indicated that these barriers are compro-
mised in an animal model of ALS. Originally, we showed structural
and functional impairment of BBB/BSCB in G93A SOD1 mice at
both early and late disease stages [8,9]. Evans Blue leakage,
downregulation of Glut-1, and laminin expression were detected in
spinal cord microvessels. Importantly, capillary ultrastructure
revealed endothelial cell (EC) degeneration, which, along with
astrocyte degeneration, compromised the BBB/BSCB, resulting in
vascular leakage. These initial findings were extended, showing
endothelial damage in SOD1 mutants with different biochemical
characteristics [10]. Importantly, Zhong et al. [10] revealed for the
first time that SOD1 mutant-mediated endothelial damage leads to
BSCB breakdown prior to motor neuron degeneration and
neurovascular inflammatory response, indicating that this damage
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tight junction proteins ZO-1, occludin, and claudin-5 were also first
demonstrated before disease onset. Moreover, primary findings on
significant (30–45%) reduction in blood flow through the cervical and
lumbar spinal cord in pre-symptomatic G93A SOD1 mice [10] may
lead to vascular hypoperfusion and accelerate motor neuron
degeneration. Although reduced capillary blood flow recently was
shown in brains of ALS patients in correlation with disease severity
[11], a link between this reduction and BBB/BSCB dysfunction still
needs to be established. BBB/BSCB impairment was also found in
SOD1 rats [12,13]. Edema-linked BBB/BSCB openings and water
transport abnormalities were also noted. Additionally, microhemor-
rhages and hemosiderin deposits were found in spinal cord
parenchyma of both mouse [10] and rat [13] models of ALS
demonstrating BSCB openings. A more recent study [14] demon-
strated lost endothelium integrity by decreased mRNA transcription
of tight junction proteins in autopsied human spinal cords from both
sporadic and familial forms of ALS, strengthening the likelihood that
BSCB disruption contributes to disease progression.
Based on recent findings of CNS microvascular pathology in
ALS including compromised BBB/BSCB in both patients and
animal models, ALS can now be considered a neurovascular
disease. Neurovascular dysfunction has been shown to significantly
contribute to the pathogenesis of Alzheimer’s disease (AD) [15,16],
stroke [17,18], and multiple sclerosis [19,20]. In AD, for example,
endothelial damage through downregulation of endothelial
MEOX2 homeobox gene, a regulator of vascular differentiation,
may lead to impaired brain angiogenesis, vessel malformation and
regression, reduced capillary density and cerebral blood flow, and
BBB pathology [15]. Moreover, neurovascular and BBB mecha-
nisms may importantly contribution to both onset and progression
of AD [16].
Newly discovered EC damage in ALS, preceding entry of
harmful blood-borne substances into areas of motor neuron
degeneration, may have implications for disease pathogenesis [21].
Endothelium dysfunction in ALS may be due to impaired
endothelialization. Circulating endothelial cell (CEC) levels in
peripheral blood might correspond to endothelial damage or
dysfunction [22,23]. Increased numbers of CECs have been
detected in peripheral blood of patients with vascular diseases such
as myocardial infarction [24,25] and acute ischemic stroke [26]
correlating with plasma markers of endothelial dysfunction. We
hypothesized that elevated CEC levels reflect deterioration of the
endothelial lining in ALS as a result of BBB/BSCB breakdown.
The aim of this study was to determine the levels of CECs in the
peripheral blood of ALS patients at different stages of disease.
Results
ALS patients and healthy controls
Circulating endothelial cell (CEC) levels in peripheral blood
from thirteen ALS patients and six healthy controls were
determined using immunocytochemical analysis. Patients had
diagnoses of ALS for 23.264.2 months (range 7–53 months) with
ALSFRS-R scores of 30.162.0 (range 21–41) (Table 1). Sporadic
ALS (SALS) was indicated in eleven patients and two patients had
a familial history of ALS (FALS). At clinic visit, ALS patients had
moderate (MALS, n=6, ALSFRS-R scores of 36.462.6, range
30–41) or severe (SALS, n=7, ALSFRS-R scores of 24.660.97,
range 21–27) disease. Each healthy control scored 48. Both FALS
patients had severe stage disease. ALS patients were taking various
anti-inflammatory medications and a standard dose of riluzole.
Healthy controls were medication-free at least six months prior to
blood collection. Patients had ALS onset at upper, lower or both
limbs. No patients had bulbar onset. All study participants tested
negative for infectious diseases: HIV, hepatitis B and C, syphilis,
and HTLV I&II.
Circulating endothelial cells in peripheral blood
Immunocytochemical analysis of CD146
+ cells in peripheral blood
smears demonstrated significantly decreased CECs in MALS patients
(2.9461.09%, p,0.05) and SALS patients (1.4160.29%, p,0.01) vs.
controls (6.8561.06%) (Figure 1C). These results were confirmed by
microscopic observation of CD146
+ cells in blood smears; few
positive CECs were found in SALS or MALS patients (Figure 1A and
B). Interestingly, one FALS patient (sALS group, ALSFRS-R score
24) had the lowest numbers of CD146
+ (0.85%) cells of any patient.
Discussion
Integrity of the endothelial cell layer is normally maintained by
continuous renewal with a low basal replication rate of 0–1% per
day [22,27]. However, pathological conditions might trigger
endothelial cell response. Increased numbers of CECs, considered
detached dysfunctional endothelial cells, are associated with
endothelial damage in various vascular diseases and correlate
with plasma markers (i.e. von Willebrand factor, soluble E-selectin)
of endothelial dysfunction [22–26,28,29]. Recently, CECs have
been proposed as a specific biomarker of endothelial damage
Table 1. ALS Patient and Healthy Control Demographics.
Subject n Sex (M/F)
ALSFRS-R Score
(mean ± S.E.M.)
Age (years,
mean ± S.E.M.)
Disease Duration from
Diagnosis (months,
mean ± S.E.M.)
All ALS Patients 13 12/1 30.0862.04 53.6262.64 23.1564.20
Range: 21–41 Range: 39–69 Range: 7–53
ALS Patients with Moderate Stage (MALS) 6 5/1 36.4062.56 55.6762.70 20.0065.28
Range: 30–41 Range: 45–63 Range: 7–32
ALS Patients with Severe Stage (SALS) 7 7/0 24.5760.97 51.9064.63 25.8666.94
Range: 21–27 Range: 39–69 Range: 7–53
Healthy Control Subjects 6 3/3 4860 61.3365.28 N/A
N/A Range: 38–69 N/A
doi:10.1371/journal.pone.0010614.t001
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[30]. CECs differ from endothelial progenitor cells (EPCs) by their
origin; CECs are derived from mature endothelium and EPCs
originate from bone marrow. The EPCs circulate in the blood [31]
and can migrate to sites of endothelial injury, incorporate into the
endothelium and thereby repair damage [32]. Thus, increased
numbers of CECs reflect endothelium damage while increased
EPCs indicate repair processes [23,27,33]. However, impaired or
insufficient mobilization of circulating bone marrow derived
endothelial progenitor cells, ‘‘as a cellular reservoir to replace
dysfunctional endothelium’’, might contribute to dysfunction of
endothelium and further disease progression [24].
The present study examined CEC levels in the peripheral blood
smears from ALS patients at different disease stages. CECs in ALS
patients at moderate or severe stages of disease and age matched
healthy controls were evaluated by immunocytochemistry using
CD146 marker, a 130 kDa membrane glycoprotein. Analysis of
CECs showed a significant decrease of CD146
+ cells in patients
with either moderate or severe course of disease. These results
conflict with the hypothesis of detaching dysfunctional endothelial
cells [23,33]. In healthy adults, CECs are rarely detected [22,27].
More than 2 fold and 6 fold decreased CECs found in MALS and
SALS patients, respectively, from control subject levels might
indicate different mechanisms of endothelial damage and/or
repair. Possibly, dysfunctional or damaged endothelial cells did not
detach from the endothelium and remained within the endothelial
layer. ‘‘Healthy’’ cells, presumably differentiated EPCs, may be
attaching atop damaged cells, forming a multilayer endothelium.
We base this suggestion on observations from a previous G93A
mouse study [8], noting numerous capillaries surrounded by
multiple layers of endothelial cells and basement membrane in the
brainstem and spinal cords of these mice compared to the
monolayer endothelium found in control mice. The outer layer of
endothelium in symptomatic G93A mice contained swollen
endothelial cells with severely vacuolated cytoplasm and intracel-
lular edema. In our ongoing study (unpublished data), ultrastruc-
tural examination of BBB/BSCB condition in the post-mortem
brainstem and spinal cord of ALS patients showed multiple
endothelial layers in some microvessels. Possibly, degenerate
abluminal endothelial cells are removed by perivascular macro-
phages. Although needing confirmation, this could explain the
limited appearance of CECs in blood of ALS patients.
Since ALS is a progressive disorder, further endothelial cell
alterations could appear during the disease course. Damage of
endothelial cells can be due to cell activation by pro-inflammatory
cytokines, various growth factors, infectious agents,or oxidativestress.
Sufficient evidence exists of inflammatory reactions in ALS. In the
brain and spinal cord of both ALS patient and animal models, large
numbers of activated microglia and astrocytes, along with inflam-
matory cell infiltration, have been observed [34–41]. These
inflammatoryeffectorscansecretenumerousinflammatorycytokines.
Increased macrophage-secreted cytokines such as interleukin (IL) 1a,
IL 1b and IL 1RA [42], cyclooxygenase type 2 (Cox-2) enzyme
[34,43,44], and up-regulation of the tumor necrosis factor-alpha
(TNF-a) gene [42,45], and inducible nitric oxide syntheses [46] make
these pro-inflammatory cytokines and enzymes likely candidates for
the effectors damaging not only motor neurons but also endothelial
cells. Moreover, IgG has been noted in ventral horn endothelial cells
of post-mortem spinal cord from ALS patients [47]. Additionally,
SOD1 mutations might further endothelial cell damage in FALS by
Figure 1. Immunocytochemical analysis of CD146
+ cells in whole blood smears. (A) A few positive CD146 cells (red, arrows) were found in
blood smears of control subjects and (B) even fewer in MALS or SALS (red, arrow) patients. Asterisks indicate CD146
2 cells in A and B. Images are
merged with DAPI counterlabeled nuclei (blue). Scale bar in A and B is 50 mm. (C) Percentages of CD146
+ cells significantly decreased in MALS and
SALS patients compared to healthy controls. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0010614.g001
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could induce endothelium impairment leading to BBB/BSCB
breakdown. Therefore, evaluation of plasma markers of endothelial
dysfunction or damage such as von Willebrand factor and soluble E-
selectin might be important.
Additionally, molecular mechanisms of vascular dysfunction
and vascular contributions to motor neuron degeneration in ALS
should receive special attention. Possibly those specific factor
alterations may affect endothelial cell damage. It has been shown,
for example, that overexpression of the two transcription factors,
serum response factor and myocardin, in the cerebral vascular
smooth muscle cells in AD, mediated arterial hypercontractility
leading to reduced cerebral blood flow [48] and facilitated cerebral
amyloid angiopathy via accumulation of the cytotoxic amyloid
beta-peptide in cerebral vessels [49] leading to disease progression.
Alternatively, the mechanism of the endothelial cell layer repair
might be impaired in ALS due to insufficient numbers of EPCs
mobilized from bone marrow. Although established markers for EPC
levels in blood were not examined, it has been showed that CD146
+
circulating cells, beside CECs, contain a subpopulation of EPCs [50].
Hence, decreased CECs in peripheral blood of ALS patients might
indicate inadequate EPC numbers which impair endothelial cell
replacement and thereby compromise integrity of the BBB/BSCB in
ALS. If this is an issue, approaches for enhancing capillary integrity in
the CNS should be developed. One possible approach is cell therapy
with the goal of replacing ECs and/or stimulating production of
EPCs. Another possibility is protecting the endothelial cell lining by
direct cytoprotection or by eliminating microenvironment influences.
Promising results have been achieved after intraperitoneal adminis-
tration of activated protein C (APC) or APC analogs, which have
anticoagulant and cytoprotective activities, into G93A SOD1 mice
after disease onset. This administration retarded disease progression
and increaselifespan by extension duration of the symptomatic phase
[51]. These beneficial APC effects were attended by transcriptional
downregulation of mutant SOD1 in motor neurons, microglia, and
cells comprising microvessels, but not mediated by SOD1 reduction
within endothelial cells. It is possible that a more neuroprotective
effectcanbeattainedbyAPCadministrationintosystemiccirculation
since it crosses the BSCB via endothelial protein C receptor.
In summary, our results suggest that endothelial damage and
impaired endothelium repair occur in ALS leading to BBB/BSCB
impairment. However, CECs did not reflect endothelial state in
ALS. It is possible that mechanisms of endothelial damage and
repair, other than detachment of dysfunctional endothelial cells,
occur in ALS. Establishing additional indicators of endothelial
dysfunction or damage is important for the evaluation of BBB/
BSCB status in ALS patients during disease progression. We
believe that results of the present study might aid researchers and
clinicians in understanding disease-related endothelium damage
and in developing effective treatments for ALS.
Materials and Methods
Ethics Statement
Patients gave informed written consent prior to inclusion in the
study. This study was approved by the Ethics Committees/
Institutional Review Board of the University of South Florida
(USF, IRB #103861). The study was conducted according to
International standards of Good Clinical Practice-(ICH guidelines
and the Helsinki Declaration).
Subjects
Thirteen clinically definite ALS patients (12 males and 1 female,
mean age 53.662.6 years) and six healthy controls (3 males and 3
females, mean age 61.365.3 years) entered our study, visiting the
University of South Florida clinic (Table 1). All patients and
controls were Caucasian. Diagnoses of ALS were previously
established according to the EI Escorial Word Federation of
Neurology criteria [52,53] at various ALS clinics/centers. The
Revised ALS Functional Rating Scale (ALSFRS-R), scored from 0
to 48, was used to evaluate overall patient functional status [54].
The ALSFRS-R score was updated for each patient when blood
was drawn. Control subjects had no neurological, immunological
or psychiatric disease. Each participant in the study signed an
informed consent form prior to enrolling.
Collection of peripheral blood samples
The peripheral blood samples (,90 ml) were obtained by
venipuncture from each patient and healthy control in accordance
with study protocols. Blood was drawn and collected into a sterile
10 ml tube (BD Vacutainer, REF 366643) containing K2 EDTA
(K2E) and a sterile 10 ml tube with a silicone coated interior (BD
Vacutainer, Serum, REF 367820) containing a clot activator. A
portion of each collected blood sample was sent to the Oklahoma
Blood Institute (Oklahoma, OK) for infectious disease (HIV, hepatitis
B and C, syphilis, CMV, and HTLV I&II) testing. Another portion of
the sample was used for blood smears in this study while the
remaining blood is being stored for use in later additional studies.
Blood smears from each blood sample were fixed in methanol
(Fisher Scientific) for 5 min for immunocytochemical analysis of
CECs. Blood smears were stored at 220uC.
Immunocytochemical analysis of CECs in peripheral
blood
The blood smears were used for immunocytochemical analysis
of CECs by CD146 antibody. Blood smears were rinsed three
times for 10 min each with 0.1 M PBS (pH 7.2). The mouse
monoclonal anti-human antibody CD146 (1:200, Chemicon) was
applied to each slide after 60 min pre-incubation with 10%
normal goat serum (Vector) and Triton X100 in PBS. After
incubating overnight at 4uC, slides were washed three times in
PBS and incubated with goat anti-mouse secondary antibody
conjugated to rhodamine (1:1200, Alexa Flour 594, Invitrogen) for
2 hrs at room temperature. The slides were then rinsed in PBS,
coverslipped with Vectashield (DAPI, Vector) and examined
under an epifluorescence Olympus BX60 microscope. The
CD146
+ cells were counted in the entire slide. The percentage
of CD146
+ cells was determined from the total number of DAPI
stained MNC cells.
Statistical Analyses
Data are presented as means 6 S.E.M. Data showed normal
distribution and were analyzed by a one-way ANOVA with
Tukey-Kramer Multiple Comparison post-hoc test. GraphPad
InStat (GraphPad Software, Inc.) software was used.
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